Products for Research Use Only
RegisterLogin

DY268

CAT: 0804-HY-110267-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-110267-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
DY268 is a farnesoid X receptor (FXR) antagonist (IC50=7.5 nM) . It inhibits FXR transactivation in a cell-based assay with an IC50 value of 468 nM. DY268 can be used in the study of drug-induced liver injury (DILI) [1][2].
CAS Number
1609564-75-1
UNSPSC
12352005
Target
FXR
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/dy268.html
Purity
99.32
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C1=CN(CC2=CC(OC)=CC=C2)N=C1C3=CC=C(C)C=C3)NC4=CC=C(C)C(S(=O)(N5CCOCC5)=O)=C4
Molecular Formula
C30H32N4O5S
Molecular Weight
560.66
References & Citations
[1]Yu DD, Lin W, Forman BM, Chen T. Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor. Bioorg Med Chem. 2014 Jun 1;22 (11) :2919-38. |[2]Kyounghwa Jung, et al. Farnesoid X Receptor Activation Impairs Liver Progenitor Cell-Mediated Liver Regeneration via the PTEN-PI3K-AKT-mTOR Axis in Zebrafish. Hepatology. 2021 Jul;74 (1) :397-410.|[3]Leah M Norona, et al. In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk. Arch Toxicol. 2020 Sep;94 (9) :3185-3200.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
BA7729-10DY268

Popular Products